Ivabradine Therapy for Heart Failure

Primary Indication: Heart Failure with Reduced Ejection Fraction

The American College of Cardiology recommends ivabradine for patients with HFrEF, LVEF ≤35%, NYHA class II-III symptoms, sinus rhythm with resting heart rate ≥70 bpm, and on maximally tolerated beta-blocker dose or with beta-blocker contraindication 1, 2, 3
Beta-blocker optimization must occur before considering ivabradine, as only 25% of patients in the pivotal SHIFT trial were on optimal beta-blocker doses, yet beta-blockers have proven mortality benefits that ivabradine does not 1, 2, 4
The benefit of ivabradine was driven entirely by reduction in HF hospitalization, not mortality 1, 2, 3

Ivabradine demonstrates antianginal and anti-ischemic efficacy equivalent to beta-blockers and calcium channel blockers in patients with heart rate ≥70 bpm 5
In patients with hypotension where blood pressure-lowering agents are problematic, ivabradine is preferable as it reduces heart rate without affecting blood pressure or contractility 5

The American Heart Association recommends regularly monitoring cardiac rhythm and discontinuing ivabradine immediately if atrial fibrillation develops, as ivabradine increases atrial fibrillation risk (5.0% vs 3.9% per patient-year with placebo) 6, 7, 8
Bradycardia occurred in 6.0% per patient-year (2.7% symptomatic) versus 1.3% with placebo, and risk factors include sinus node dysfunction, conduction defects, ventricular dyssynchrony, and concurrent negative chronotropes 7

The European Society of Cardiology advises against using ivabradine as first-line therapy - it is adjunctive therapy only after beta-blocker optimization 1, 2, 4
The American College of Cardiology recommends avoiding combination of ivabradine with non-dihydropyridine calcium channel blockers (diltiazem, verapamil) due to excessive heart rate lowering and increased ivabradine exposure 5, 6, 7

The American College of Cardiology, American Heart Association, and Heart Rhythm Society recommend that ivabradine is contraindicated in decompensated heart failure, as stated in their 2016 guidelines 9
The European Society of Cardiology emphasizes that ivabradine is contraindicated in patients with atrial fibrillation and notes concerns about use in unstable patients, according to their 2018 guidelines 10
The American College of Cardiology Expert Consensus specifies that ivabradine is indicated only for patients mainly in sinus rhythm, not in those with persistent or chronic atrial fibrillation, those experiencing 100% atrial pacing, or unstable patients, as stated in their 2021 guidelines 11

The use of ivabradine in decompensated heart failure may worsen cardiac output due to hemodynamic instability, and it lacks mortality benefit, even in stable chronic heart failure, as noted in the 2021 American College of Cardiology guidelines and the 2012 European Heart Journal 11, 12
Beta-blockers have proven mortality benefits in heart failure, while ivabradine does not, making beta-blocker optimization a priority over ivabradine use, as stated in the 2021 American College of Cardiology guidelines 11

Ivabradine is appropriate for patients with stable chronic symptomatic heart failure with reduced ejection fraction (HFrEF), who have a left ventricular ejection fraction (LVEF) ≤35%, New York Heart Association (NYHA) class II-III, sinus rhythm, and a resting heart rate ≥70 bpm, and who are on maximally tolerated beta-blocker or have a beta-blocker contraindication, as recommended by the 2021 American College of Cardiology guidelines 11